Spotlight on quadrivalent human papillomavirus(Types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant-genital lesions, genital cancer, and genital warts in women

BioDrugs

Volumn 25, Issue 5, 2011, Pages 339-343

  McCormack, Paul L ^a   Joura, Elmar A ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

Adis Spotlights; Cervical cancer; Human papillomavirus infections; Human papillomavirus vaccine recombinant quadrivalent

Indexed keywords

DIPHTHERIA VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CONDYLOMA ACUMINATUM; DRUG COST; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GENITAL SYSTEM DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; PAIN; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; SCREENING TEST; SEROCONVERSION; SYNCOPE; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; CHILD; CONDYLOMATA ACUMINATA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 80053200027     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11205060-000000000-00000     Document Type: Article

References (49)

1. European Medicines Agency. Gardasil (human papillomavirus vaccine [types 6, 11, 16, 18] recombinant, absorbed): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/Hu mans/EPAR/gardasil/gardasil.htm [Accessed 2010 Oct 11]
2. Merck&Co.Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant]: US prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi-circulars/g/gardasil/gar dasil-pi.pdf [Accessed 2010 Nov 9]
3. Stanley M. Prophylactic HPV vaccines. J Clin Pathol 2007 Sep; 60 (9): 961-5 (Pubitemid 47441926)
4. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006 Aug 31; 24 Suppl. 3: S3-11-25
5. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 Aug 31; 24 Suppl. 3: S3-35-41
6. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J InfectDis 2009 Mar 15; 199 (6): 805-14
7. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix-andGardasil- human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009 Oct; 5 (10): 705-19
8. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008 Dec 9; 26 (52): 6844-51
9. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 May; 6 (5): 271-8 (Pubitemid 40590263)
10. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006 Jul 7; 24 (27-28): 5571-83 (Pubitemid 44172918)
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 May 10; 356 (19): 1928-43 (Pubitemid 46740303)
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007May 10; 356 (19): 1915-27
13. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007 Jun 21; 25 (26): 4931-9 (Pubitemid 46843434)
14. Muñoz N, Manalastas Jr R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009 Jun 6; 373 (9679): 1949-57
15. Garland SM, Steben M, Hernandez-Avila M, et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 2007 Jun; 14 (6): 792-5 (Pubitemid 47104771)
16. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil- cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007 Jul 31; 3 (4): 109-15 (Pubitemid 47501028)
17. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007 Mar; 26 (3): 201-9 (Pubitemid 46340765)
18. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov; 118 (5): 2135-45 (Pubitemid 46393698)
19. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008 Jan 30; 26 (5): 686-96
20. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010 Apr; 29 (4): 314-8
21. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010 Jun; 125 (6): 1142-51
22. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly osequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28 (18): 3171-9
23. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2009 Oct; 2 (10): 868-78
24. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 Jun 2; 369 (9576): 1861-8 (Pubitemid 46829356)
25. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 Dec 4; 95 (11): 1459-66 (Pubitemid 44863348)
26. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009 Oct 14; 5 (10): 696-704
27. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007 Nov 15; 196 (10): 1438-46
28. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009 Apr 1; 199 (7): 926-35
29. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009 Apr 1; 199 (7): 936-44
30. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011 Jan; 11 (1): 39-44
31. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2010 Feb; 29 (2): 95-101
32. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009 Aug 19; 302 (7): 750-7
33. Annemans L, Rémy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 (3): 231-45
34. Kulasingam SL, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6: 4
35. Bergeron C, Largeron N,McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008 Winter; 24 (1): 10-9 (Pubitemid 351158538)
36. Mennini FS, Rossi PG, Palazzo F, et al. Health and economic impact associatedwith a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009 Feb; 112 (2): 370-6
37. Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24 (5): 1473-83 (Pubitemid 351741581)
38. BrissonM,Van de VeldeN,DeWals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 Jul 20; 25 (29): 5399-408 (Pubitemid 46977529)
39. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008 Feb; 14 (2): 244-51 (Pubitemid 351213674)
40. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010 Apr; 20 (2): 213-9
41. Dasbach EJ, Largeron N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res 2008 Oct; 8 (5): 491-500
42. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008 Jul; 115 (8): 947-56 (Pubitemid 351841762)
43. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination inMexico: a transmission dynamic model-based evaluation. Vaccine 2007 Dec 21; 26 (1): 128-39 (Pubitemid 350218187)
44. Jit M, Choi YH, EdmundsWJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008 Aug 9; 337 (7665): 331-5
45. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007 Jan; 13 (1): 28-41 (Pubitemid 46057835)
46. Dasbach EJ, Nagy L, Brandtmüller A, et al. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010 Mar; 13 (1): 110-8
47. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008 Aug 21; 359 (8): 821-32
48. Olsen J, Jepsen MR. Human papillomavirus transmission and cost- ffectiveness of introducing quadrivalent HPV vaccination inDenmark. Int J Technol Assess Health Care 2010 Apr; 26 (2): 183-91
49. McCormack PL, Joura EA. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs 2010; 70 (18): 2449-74